FDA Redraws the Map for AI Wearables — And the Implications Reach Well Beyond Silicon Valley
FDA's 2026 guidance exempts wellness-category wearables from premarket review. For European health tech companies under MDR/IVDR, this creates both commercial pressure and a strategic opening.
By Paal Selnaes, Norseman Projects Ltd
At CES 2026, FDA Commissioner Marty Makary announced two landmark guidance updates affecting AI-powered wearables and clinical decision support tools. For European health tech companies navigating both EU MDR/IVDR and US market entry, the shift creates real commercial pressure — and a strategic opening that is worth understanding clearly.
What the FDA Actually Said
🔬 The Guidance Update
Wearables and AI-driven clinical decision support tools that remain in “general wellness” territory no longer require FDA premarket review. Blood pressure monitoring, blood oxygen saturation, and glucose signals are explicitly included — provided companies make no diagnostic or medical-grade claims. A full AI regulatory framework is the stated next step.
The headline reads as a straightforward win for speed-to-market. US-based competitors can now ship wellness-category connected health products faster, with less formal oversight. That part is real. But the full picture is more nuanced — and for European companies, more interesting.
The Burden of Proof Has Not Disappeared — It Shifted
Reduced FDA oversight does not mean reduced accountability. With premarket review removed for the wellness category, the discipline of claims architecture falls entirely on the manufacturer. The line between a “wellness insight” and a “clinical recommendation” is thin, and crossing it still triggers full device regulation — with post-market consequences that are considerably harder to manage than pre-market requirements.
⚠ The Claims Architecture Risk
Companies that move quickly without a rigorous internal framework for distinguishing wellness claims from clinical claims are not avoiding regulatory risk — they are accumulating it. Validation rigour needs to increase as formal oversight decreases. The FDA's enforcement posture on misclassified products has historically been unforgiving.
The European Position: Pressure and Opportunity
For European health tech companies, this guidance creates two simultaneous dynamics that need to be held together — not resolved in favour of one or the other.
Commercial Pressure
US Competitors Can Move Faster
Domestic US competitors now face a lighter regulatory path to market in the wellness category. For European companies already working through MDR or IVDR conformity assessment — a process designed for a higher bar — this represents a real speed disadvantage in the short term.
Strategic Opportunity
MDR/IVDR Is Now a Differentiator
EU-certified products carry demonstrable credibility on algorithmic transparency, clinical evidence standards, and post-market surveillance. In a US market where self-policing is now the norm for wellness products, that documented rigour is a positioning asset — particularly for enterprise, clinical, and insurance-channel buyers who will increasingly distinguish between self-certified and externally validated products.
How the Two Regulatory Environments Now Compare
| Dimension | US (Post-CES 2026) | EU (MDR / IVDR) |
|---|---|---|
| Wellness category | No premarket review required | Risk classification determines pathway |
| Clinical claims | Full device regulation triggered immediately | Notified Body involvement for Class IIa+ |
| AI transparency | Self-policed under wellness exemption | Technical documentation and clinical evaluation required |
| Post-market surveillance | Manufacturer-defined for wellness | Structured PMS plan mandatory |
| Speed to market | Fast for wellness-classified products | Longer — but produces documented clinical evidence that carries weight in US B2B and clinical channels |
What This Means for Market Entry Strategy
Claims architecture review is now a priority task
Before entering the US market, every product feature that touches health data needs a documented, defensible rationale for why it falls within — or outside — the wellness exemption boundary.
MDR/IVDR documentation is a commercial asset, not just a compliance cost
Reframe it in customer-facing materials, particularly for B2B, clinical, and insurance-channel buyers. The companies that distinguish between self-certified and externally validated products are exactly the buyers Norseman clients are targeting.
The window to shape market position is open now
The FDA has signalled a full AI regulatory framework is forthcoming. Companies that establish credibility on clinical evidence, algorithmic transparency, and post-market rigour before that framework lands will have a structural advantage over those who moved fast and are now retrofitting compliance.
Dual-market strategy is increasingly viable
With the US wellness pathway now faster, European companies with MDR/IVDR products can consider launching in the US wellness category first — building revenue and market presence — while retaining the clinical evidence base for a subsequent medical-grade positioning.
At Norseman Projects, we track how regulatory shifts on both sides of the Atlantic affect product strategy and market entry for technology companies in health, wireless, and connected devices. The FDA's direction of travel is clear. The companies that will benefit most are those that treat regulatory intelligence as a strategic input — not a downstream compliance task.
Need a tailored market-entry or regulatory strategy?
We help European technology companies translate complex U.S. and Canadian regulatory pathways into executable plans — from FCC and PTCRB through FDA and ITAR/EAR.